Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

763 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
German specialists treating testicular cancer follow different guidelines with resulting inconsistency in assessment of retroperitoneal lymph-node metastasis: clinical implications and possible corrective measures.
Schoch J, Haunschild K, Strauch A, Nestler K, Schmelz H, Paffenholz P, Pfister D, Persigehl T, Heidenreich A, Nestler T. Schoch J, et al. Among authors: heidenreich a. World J Urol. 2023 May;41(5):1353-1358. doi: 10.1007/s00345-023-04364-5. Epub 2023 Apr 4. World J Urol. 2023. PMID: 37014392 Free PMC article.
Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue.
Nestler T, Kremer L, von Brandenstein M, Wittersheim M, Paffenholz P, Wagener-Ryczek S, Quaas A, Hellmich M, Müller S, Pfister D, Odenthal M, Heidenreich A. Nestler T, et al. Among authors: heidenreich a. Cancer. 2023 Feb 15;129(4):634-642. doi: 10.1002/cncr.34571. Epub 2022 Dec 11. Cancer. 2023. PMID: 36504384 Free article.
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Fizazi K, King JM, Adra N, Douglawi A, Cary C, Sweeney C, Fankhauser CD. Antonelli L, et al. Among authors: heidenreich a. Eur J Cancer. 2023 Mar;182:144-154. doi: 10.1016/j.ejca.2022.12.032. Epub 2023 Jan 20. Eur J Cancer. 2023. PMID: 36787661 Free article.
Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer.
Rosenbrock J, Baues C, Kreis M, Fouassi R, Celik E, Paffenholz P, Pfister D, Heidenreich A, Marnitz S. Rosenbrock J, et al. Among authors: heidenreich a. Strahlenther Onkol. 2023 Jun;199(6):574-584. doi: 10.1007/s00066-023-02060-2. Epub 2023 Mar 17. Strahlenther Onkol. 2023. PMID: 36930248 Free PMC article.
Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment.
Majewski M, Paffenholz P, Ruf C, Che Y, Seidel C, Heinzelbecker J, Schmelz HU, Matthies C, Albers P, Bokemeyer C, Heidenreich A, Pichler M, Nestler T; GTCSG (German Testicular Cancer Study Group). Majewski M, et al. Among authors: heidenreich a. Cancer Med. 2023 Aug;12(16):16829-16836. doi: 10.1002/cam4.6304. Epub 2023 Jul 1. Cancer Med. 2023. PMID: 37392170 Free PMC article.
763 results